Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Boehringer Ingelheim’s Pradaxa passes one million patient-years

Boehringer Ingelheim’s Pradaxa passes one million patient-years

31st August 2012

Boehringer Ingelheim has revealed that combined treatment experience with its blood-thinning drug Pradaxa has crossed one million patient-years.

The drug, which has been approved in more than 70 countries for the prevention of thromboembolic events in patients after surgery and with non-valvular atrial fibrillation, now possesses the largest body of clinical experience among all novel oral anticoagulants.

According to the manufacturer, this shows the strong level of approval Pradaxa has received from clinicians, having demonstrated its safety and efficacy in various clinical trials.

It is estimated that the drug has saved 40,000 people from suffering a stroke related to non-valvular atrial fibrillation.

Professor Klaus Dugi, corporate senior vice-president for medicine at Boehringer Ingelheim, said: "It is great to see this treatment being accepted and adopted all over the world for the benefit of patients being effectively protected against thromboembolic events."

This comes after data from the company's global RE-LY atrial fibrillation registry showed that Pradaxa could play a role in addressing inequality and variations in treatment quality across the world.ADNFCR-8000103-ID-801440454-ADNFCR

We currently have 10 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.